<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Felipe Nogueira, PhD on Medium]]></title>
        <description><![CDATA[Stories by Felipe Nogueira, PhD on Medium]]></description>
        <link>https://medium.com/@felipenogueiraphd?source=rss-64c6ffdb6db2------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/1*cX4UT8hHePoC7rbEOoUSFQ.jpeg</url>
            <title>Stories by Felipe Nogueira, PhD on Medium</title>
            <link>https://medium.com/@felipenogueiraphd?source=rss-64c6ffdb6db2------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 13:01:38 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@felipenogueiraphd/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Skepticism about cancer screening: An Interview with Dr. H. Gilbert Welch]]></title>
            <link>https://felipenogueiraphd.medium.com/skepticism-about-cancer-screening-an-interview-with-dr-h-gilbert-welch-ad6b5a56f593?source=rss-64c6ffdb6db2------2</link>
            <guid isPermaLink="false">https://medium.com/p/ad6b5a56f593</guid>
            <dc:creator><![CDATA[Felipe Nogueira, PhD]]></dc:creator>
            <pubDate>Fri, 19 Feb 2021 04:19:19 GMT</pubDate>
            <atom:updated>2021-02-19T04:19:19.199Z</atom:updated>
            <content:encoded><![CDATA[<p>Published in <a href="https://skepticalinquirer.org/volume/no-1-vol-44/"><em>Skeptical Inquirer Vol 44, №1</em></a><em> </em>(Jan/Feb 2020)</p><p><a href="https://drive.google.com/file/d/1PAfdhUBK63TzYGDFCkHaGUvGpUi5tKDk/view">Original PDF file here</a></p><p>Dr. H. Gilbert Welch is an American physician and cancer screening researcher. As a former Professor in Dartmouth Institute for Health Policy and Clinical Practice, he has published many peer-reviewed papers about the harms of early detection and specifically, cancer screening — the systematic search for cancer before it causes symptoms.</p><p>Welch is also a science writer. His first book, published in 2004, is <em>Should I Be Tested For Cancer? Maybe Not and Here’s Why</em>. Welch, along with researchers Lisa Schwartz and Steven Woloshin, wrote <em>Overdiagnosed — Making People Sick in the Pursuit of Health</em>, which deals with screening and other cases where medicine has been too much, probably causing more harm than good. His latest book was published in 2015 and is titled <em>Less Medicine, More Health — 7 Assumptions That Drive Too Much Medical Care.</em></p><p>In this interview, Welch and I discussed about why diagnosing a cancer early does not necessarily mean it is always a good thing.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/320/0*i0971cBiW95wrV0L.jpg" /><figcaption>Dr. H Gilbert Welch</figcaption></figure><p><strong><em>Nogueira</em>: When we are discussing problems of screening, how can we get the message clear for the people not to be confused that all medical care is being criticized?</strong></p><p><strong><em>Welch:</em> </strong>I am a conventionally trained physician and I believe medical care can do a lot of good — particular for people who are sick and injured. Making a timely diagnosis in people who are sick is really important. What I am worried about is when medical care expands to the population that is well — because it is hard to make a well person better, but it is not that hard to make them worse.</p><p>We might involve a thousand people in a screening program for ten years and one person is helped. This is good, but an important question is: What happened to the other 999? That is where I have been in my career for the last 20 years.</p><p><strong><em>Nogueira</em>: What is the main idea behind screening and its problems?</strong></p><p><strong><em>Welch</em>:</strong> In the past, doctors waited for problems to develop in a population and made diagnosis and treatment in that fraction. The idea of screening or early detection is to advance in time the moment of diagnosis in the same population. The assumption behind screening is: the people diagnosed early will be those destined to develop problems.</p><p>However, the reality has been different: whenever we look hard for early forms of disease, we find that more people have them. Thus, not all of them will develop problems. As we do not know who is going to develop problems, we tend to treat all of them. This means we are treating some people for whom the disease would never be a problem — it is the overdiagnosed and needlessly treated fraction. They cannot be helped, but they can be harmed.</p><p>Overdiagnosis happens to a relatively few individuals. A more common problem of screening is the disease scare — a false positive result. Many individuals require multiple visits and multiple tests before we are sure they don’t have cancer. Patients understand medications can have harms, but they cannot imagine how a test could have harms. They think that it is always good to know, but they do not recognize the cascade of events that a test can trigger. Even a perfectly safe test can lead to a series of events that can harm people</p><p>Finally, to promote screening we need to scare people about the disease (“that’s why you need to be screened”). In other words, we are making everybody more worried about the future. Ironically, part of being healthy is being not too worried about health. Screening is responsible for injecting some “dis-ease” into the population.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/227/0*NogcnXg9wmDS6tF3.jpg" /><figcaption>Cover — Skeptical Inquirer 44.1</figcaption></figure><p><strong><em>Nogueira</em>: What is the effect of screening/early detection in survival statistics?</strong></p><p><strong><em>Welch</em>: </strong>With more detection, the typical patient now does better. Among patients with the disease, they appear to have survived longer. This happens because people overdiagnosed or with less severe forms of disease are included in the “disease” group. Screening effects are really misleading: the harder you look, the more you find and everyone appears to be better. It is related to the popularity paradox of screening: the more overdiagnosis screening causes, the more popular screening becomes.</p><p><strong><em>Nogueira</em>: What have we learned about cancer progression and its relationship with screening?</strong></p><p><strong><em>Welch</em>: </strong>Cancer is much more heterogeneous than we thought. Abnormalities that meet the pathological definition of cancer could have very different natural histories; they have variable growth rates.</p><p>It has been described as the barnyard pen of cancers. There are three animals in the barnyard: the birds, the rabbits and the turtles. The goal of screening is fence them in — to catch them early. However, we cannot catch the birds, because they are already gone. Birds are the most aggressive cancers; they have already spread by the time they are detectable. Screening does not help with those cancers. Sometimes we can treat them, but they are the worst type.</p><p>It is possible to catch the rabbits if you build enough fences. The rabbits are the cancers that can be detected earlier and will bother patients. So screening may help in these cases. For screening to be of help, treatment needs to be more effective early than it is late. Sometimes this is not true. In the case of breast cancer, a two-centimeter tumor can be treated as well a one-centimeter tumor.</p><p>Finally, we don’t need any fences for the turtles — because they are not going anywhere. Turtles meet the pathological definition of cancer. However, they are either not growing or growing so slowly that they will never cause problems until the patient dies from something else. Or they are regressing — some cancers start and they disappear; perhaps recognized by a well-functioning immune system.</p><p>The unfortunate reality is that screening is very good at finding turtles. Doctors are not able to distinguish turtles from rabbits, thus we treat everybody — creating the major harm of early detection: overdiagnosis and overtreatment.</p><p><strong>Nogueira: How has screening affected the incidence of prostate cancer?</strong></p><p><strong><em>Welch</em>: </strong>Note how the incidence of prostate cancer in US bounces around (see Figure 1). There is no known tumor biology or carcinogenic process that can explain this graph. It looks more like a financial chart than a cancer incidence chart. And this is not a small number problem; it is the most common cancer in the database</p><p>The graph can be divided in four phases. It begins in 1975 with the growth of Transurethral resection of the prostate (TURP), which at the time was a common prostate surgery done to help men with large prostates. With more pieces of prostates being sent to pathologists, the incidence of prostate cancer slowly increased. The second phase is PSA promotion, when hospitals started to offer free PSA test, knowing they would make their money back in subsequent blood tests, biopsies and treatments. Around 1995, the retrenchment era begun with urologists recognizing that they should not offer PSA screening for men with less than ten years of life expectancy, since they cannot be helped by screening. Finally, the discouragement took place after the US Preventive Services Task Force argued against PSA screening. It is remarkable the incidence at present is almost the same of 1975. In other words, this is a scrutiny-dependent cancer. I do not know of more powerful example of how the health care system affects the apparent amount of cancer.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/0*DrS9YRdzdjVzZvzV.png" /><figcaption>Figure 1 — Age-adjusted incidence of prostate cancer in the United States during 1975–2014 (Welch and Brawley 2018).</figcaption></figure><p><strong><em>Nogueira</em>: Among common cancer screening programs (for cervical, colorectal, breast and prostate cancer), what are their effects in the mortality of those cancers?</strong></p><p><strong><em>Welch</em>: </strong>We never had a randomized trial of cervical cancer screening; it was implemented before we considered randomized trials. There is a lot of observational data that suggests it is helpful, but it does not explain the 80% reduction in cervical cancer mortality. For instance, we have seen an 80% reduction in stomach cancer mortality and it is a cancer that we do not screen for. Colon cancer mortality is also declining and the fall started before the introduction of screening.</p><p>Screening for cervical cancer and colorectal cancer has had some effect in the mortality of those cancers. Breast cancer screening has had only a little effect on breast cancer mortality. The big effect in breast and prostate cancer is better treatment — we learned those cancers are hormonal diseases.</p><p><strong><em>Nogueira</em>: How do you see the risk and benefit ratio of those cancer screening programs?</strong></p><p><strong><em>Welch</em>: </strong>In general, people consider colorectal and cervical cancer screening in the side of more benefit than harm. I think this is largely because the problem of cancer overdiagnosis is less evident in those cases. Since they detected precancerous lesions, overdiagnosis takes place at a prior step — dysplastic polyps or cervical dysplasia. In colorectal cancer screening, there are complications from colonoscopy and from polypectomies (e.g. bleeding, perforations). In cervical cancer screening, there are complications from cryotherapy and excisions for precancerous lesions. (e.g. bleeding, preterm birth)</p><p>Cancer screening has a mix of effects. Most screening, including PSA and mammography, does help a few people, but also harm others. This is the conundrum we must be clear about. So, screening is not a public health imperative; it’s a choice.</p><p>And it can distract people from more important things they can be doing for their health. It can also distract resources from other more important interventions. There are two very different aspects to the word <em>prevention</em>. One is health promotion from behavior advices, such as do not smoke, eat real food, move regularly, and find meaningful relationships. They are not sexy or technological, but are very important to health. But when the prevention movement got medicalized, it became a technological imperative to look for early forms of disease.</p><p>We also have to be sensible with the overdiagnosis problem. We have to stop thinking the best test as the one that finds more cancers. Typically that is how tests are promoted, “this test finds more cancer than that”. That is not a good test; we are <em>not </em>looking to find more cancers; we want to find a few cancers that <em>matter</em>.</p><p><strong><em>Nogueira</em>: How can we make screening better, for instance to find those cancers we can make a difference on?</strong></p><p><strong><em>Welch</em>: </strong>This is best exemplified in the case of lung cancer screening. In the US, lung cancer is the most common cause of cancer death; it is a big problem. There is really well-defined risk group, which can be identified by a single question “Do you smoke?” We have a really common cause of death and an easy way to find a high risk group — it is a perfect situation for screening.</p><p>It was the first cancer studied for screening and it happened in the 1980s using chest x-ray. The results were terribly disappointing: screening led to more deaths; not less. This happened because screening triggered operations and some died from those operations. The idea of overdiagnosis in lung cancer was crazy, but it happened. Then, spiral CT comes along. Importantly, the investigators responsible for spiral CT trial knew about overdiagnosis. What they did was groundbreaking: when the spiral CT found a small lesion that looks worrisome, they did not act and did not biopsy immediately; they waited three months to see whether the lesion was growing. They were making use of the diagnostic value of time. Time provides information both about the genetics of the tumor and the body’s reaction to it. I think that is a step forward.</p><p>Everything changes when you move to a genuine high-risk population (recall that regular cigarette smokers are 20 times more likely than non-smokers to die from lung cancer). They are much less likely to be overdiagnosed and much more likely to be helped. But there are not a lot of risk factors as common and powerful as cigarette smoking. Most cancers are sporadic — not the result of some obvious risk factor.</p><p><strong><em>Nogueira</em>: All-cause mortality is not reduced in population wide cancer screenings trials. Could you explain why it matters?</strong></p><p><strong><em>Welch</em>: </strong>It begins with what counts as a cancer death. In the context of evaluating a screening, I want cancer death not only to include deaths from cancer but also deaths due to interventions performed as part of looking for and treating the cancer. That is not what happens. That is why all-cause mortality is important. If we are going to tell people that screening “save lives”, I would like to know if it changes their risk of death. Unless you want to play a game that you care more about one type of death than another.</p><p>A good example is a classic study — the Minnesota Colon Cancer Control Study. It has now 30 years of follow-up. There are three arms in the study: annual and biennial screening and control group. After 30 years, 2% of annual group and 3% of control group died from colon cancer. This is the benefit: 1%, or to put in relatively terms, a 33% reduction in colon cancer death. However, all-cause mortality was the same in all groups (Figure 2). It is hard to say that is saving lives; it may be trading one form of death for another.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/320/0*fGyvk48-a0FA9fp5.png" /><figcaption>Figure 2. The Minnesota Colon Cancer Control Study: All-cause mortality was the same between three groups: control (non-screened), annual screening, and biennial year (Shaukat et al. 2013).</figcaption></figure><p><strong><em>Nogueira</em>: Since screening benefits are not large and there are harms, what are the reasons for the heavy promotion of screening?</strong></p><p><strong><em>Welch</em>: </strong>The first is a true belief that early detection must help, as a solution to every bad disease. Money is another part, because is a great way to recruit new patients. It is good for Pharma, for test manufactures and increasingly good for our hospitals. It is a powerful idea to look for diseases early: if you could argue that everyone should do something, it is a huge market.</p><p><strong><em>Nogueira</em>: What about clinical breast examination and self-breast examination often advertised to women?</strong></p><p><strong><em>Welch</em>: </strong>The data is clear that clinical breast exam and teaching women to self-examine their breasts does not seem to help. But if a woman becomes aware of a new breast lump, she should have it evaluated. Part of the attention to breast cancer has been good. Ironically, it is possible that screening mammography could be the best way to do the clinical breast exam, if the threshold would be looking for things of 1-cm or bigger. I think a lot of harm from mammography could be reduced if the thresholds for further investigation were much higher.</p><p>The general conundrum of screening is we have to involve a whole bunch of people to potentially help a very few. We have to pay attention to not disturb the rest of them.</p><p><strong><em>Nogueira</em>:</strong> <strong><em>How do you see the paper that claimed an increase in advanced cases of prostate cancer after USPSTF 2012 recommendation against screening?</em></strong></p><p><strong><em>Welch</em>:</strong> That report — an increased number of late stages of prostate cancer — was highly flawed. They were only talking about “counts”; they never had a denominator.</p><p>In the US data so far (Figure 3), the incidence of metastatic prostate cancer at first presentation — the cancer was already metastatic at the moment of diagnosis — continues to stay stable. But I expect it will go up.</p><p>What you see is the implementation of PSA screening really had an effect on that incidence — almost cut it in half. This is a sign that the bad cancers are being found early. But now it’s been fairly stable, but I wouldn’t be surprised if go back up, because PSA screening is going down. But whether that changes death rates, it is a separate question, because early treatment must matter.</p><p>Notice, in comparison, the incidence of metastatic breast cancer at first presentation never changes, it is pretty stable. Mammography screening has not been able to reduce the amount of breast cancer diagnosed at this very late stage. That’s not the mammographers fault, that the fault of the agressive cancers (the birds in the barnyard analogy).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/0*Rtat_cbQy282gP1_.png" /><figcaption>Figure 3. Incidence of cancer that was metastatic at first presentation in the United States, 1975–2012 (Welch et al. 2015).</figcaption></figure><p><strong>References:</strong></p><p>Shaukat, A., S.J. Mongin, M.S. Geisser, et al. 2013. Long-term mortality after screening for colorectal cancer. <em>N Engl J Med</em>. 369(12):1106–14. doi: 10.1056/NEJMoa1300720.</p><p>Welch, H.G., O.W Brawley. 2018. Scrutiny-Dependent Cancer and Self-fulfilling Risk Factors. <em>Ann Intern Med.</em> 168(2):143–144. doi: 10.7326/M17–2792.</p><p>Welch, H.G., D.H. Gorski, P.C. Albertsen. 2015. Trends in Metastatic Breast and Prostate Cancer — Lessons in Cancer Dynamics. <em>N Engl J Med</em> 373:1685–1687 doi: 10.1056/NEJMp1510443</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=ad6b5a56f593" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[How Much Longer Will Cancer Screening Myths Survive?]]></title>
            <link>https://felipenogueiraphd.medium.com/how-much-longer-will-cancer-screening-myths-survive-5be177d12d9e?source=rss-64c6ffdb6db2------2</link>
            <guid isPermaLink="false">https://medium.com/p/5be177d12d9e</guid>
            <dc:creator><![CDATA[Felipe Nogueira, PhD]]></dc:creator>
            <pubDate>Wed, 29 Apr 2020 15:22:30 GMT</pubDate>
            <atom:updated>2020-04-29T15:24:12.217Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/640/0*4-KzTsusrQqu3-5_.JPG" /></figure><p>Published in <a href="https://www.skeptic.com/magazine/archives/24.4/"><em>Skeptic Vol 24, №4</em></a><em>.</em></p><p><a href="https://drive.google.com/file/d/19PwLGx-aaSPKvaZH7M6ONBbejbOC1Z0T/view"><em>Click here for original pdf file</em></a></p><p>It has been 20 years since Dr. Angela Raffle published an article in prestigious medical journal The Lancet with the provocative title “How long will screening myths survive?” [1]. Although screening myths have been discussed extensively in peer-reviewed articles since Raffle’s publication, I think the public still needs balanced information. This article will review important concepts and myths of screening.</p><p>Screening is systematic search for disease, through medical tests, in people without symptoms of the disease being screened for. Common population screening programs include screenings for breast, cervical, colorectal and prostate cancers.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/587/1*dqw4hOg59eojnrMNpZneDQ.png" /></figure><p>One of the myths discussed in Raffle’s article was regarding the comment “A recent analysis…has shown a reduction in the risk of cervical cancer by 95% for at least 8 years.” Another example is the statement made by Rudy Giuliani, former New York City Mayor who had been diagnosed with prostate cancer. When he was running for president in 2008, Giuliani tried to make a political statement that the American health system was much better than the “socialized” medicine of England, when he claimed he had an 82% of chance of surviving prostate cancer in the United States, compared to only 44% in England [2].</p><p>Probably without knowing it, Giuliani compared patients that were diagnosed in different ways, making his comparison invalid. Screening in the United States was much more common than in England. It is not possible to compare screened patients with non-screened patients due to the healthy screened-effect — people who get screened tend to be healthier, physically fit, non-smokers, and to have less social problems than those who do not get screened [3].</p><p>That is why randomization is used in clinical trials — to assure the groups are equal with the only difference being the intervention under analysis. In a screening context, however, those numbers could have come from randomized clinical trials and it still would have been misleading.</p><p>The numbers Giuliani referred to are the 5-year survival rate for prostate cancer in the United States and England in 2000. Five-year survival rate is the proportion of patients with a specific cancer who are still alive five years after the diagnosis. It is probably the most common statistic used to measure cancer prognosis [4]. The problem happens when the survival rates include screened patients.</p><p>The idea of screening is to advance in time the moment of diagnosis to allow early detection — a cancer that would have been diagnosed due to symptoms in advanced stages is now detected years before in the asymptomatic phase. Imagine that a group of patients without screening is diagnosed due to symptoms at age 63 years, but die from the cancer at 65. Now, consider that screening detects the tumor at age 59 and the patients still die from the cancer at 65. Thus, without screening the 5-year survival rate was 0%, but with screening it is 100%, even though screening did not make any of them to live longer — both group of patients died at the same time. This is called the lead time bias [2, 3] and it is illustrated in Figure 1.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/0*oz3MtkU1U5vsxuIt.JPG" /></figure><p>Another problem with screening is the length-time bias. This happens because screening is done periodically, and cancer, contrary to what most people think, is a heterogeneous disease with different progressions rates [2,3]. Really aggressive and more lethal cancers tend not to be detected by screening because they grow fast and cause symptoms between screening rounds. Similarly, screening tends to detect slow-progressive cancers. As a result, a group of patients whose cancers were detected by screening will live longer than those diagnosed clinically simple because screening selected a group of patients with a better prognosis. In fact, some of those would not have progressed or would have regressed spontaneously. That means that screening detects abnormalities that meet the pathological criteria of cancer, but would not have caused symptoms or death in the patient’s lifetime. This is called overdiagnosis [5]. The problem of overdiagnosis is that at the time of diagnosis it is not possible to know which cases will progress and which will not, so almost everyone is treated, leading to overtreatment.</p><p>Overdiagnosis also inflates the survival statistic [2, 3]. Figure 2 shows a hypothetical example. Imagine that without screening, of 1000 people with a specific cancer, after five years 900 are dead and 100 are alive. Now imagine that screening correctly identifies those 1000 patients, but also identifies 4000 patients whose cancer would not have progressed — they were overdiagnosed. Screening increased 5 year survival rate from 10% to 82%, but the number of deaths was the same in both scenarios.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/428/0*OTZwIVDvPfre_ckY.JPG" /></figure><p>Had Rudy Giuliani compared the prostate cancer mortality rates in both countries, he would have seen that they were roughly the same in 2000: 26 and 27 per 100,000 in US and England, respectively [2]. Contrary to his claim of a superior healthcare system in the US, higher survival rates and unchanged mortality actually show the opposite: Americans are more likely to be overdiagnosed and overtreated for prostate cancer, but for no reason because there is no benefit from those extra diagnosed and treated patients.</p><p>An inflated survival rate without screening saving lives is not just a speculation. In a randomized trial of chest X-ray screening for lung cancer in smokers, the 5-year survival rate was 35% for the screened group and 19% for the control group, but the mortality was slightly higher in the screened group [6]. Moreover, another study7 found no correlation between differences in 5-year survival rates and mortality rates for 20 different types of cancers in the US. Between 1950 to 1995 in the US, the most drastic change in 5-year survival rate was for prostate cancer (43% to 93%) [7], a period where the incidence of prostate cancer increased substantially especially after screening started.</p><p>The screening for neuroblastoma is another illuminating case [3]. Neuroblastoma is a cancer that occurs in children and usually has a better prognosis when it appears before age one, and a worse prognosis after that. In 1985, screening children for neuroblastoma started nationwide in Japan. Until 1988, screening detected 337 cases and they had a 97% survival rate, much higher than the 5-year survival rate of 50–55% of unscreened children. Even though screening increased considerably the incidence of neuroblastoma, the number of children diagnosed after age one did not change. More critically, the mortality of neuroblastoma in Japan was similar of other countries that had not introduced screening. Due to considerable overdiagnosis and lack of clear benefits, the neuroblastoma screening in children ended in Japan in 2004.</p><p>Despite biased survival statics being widely used for the promotion of screening, medical doctors are not informed about it. In a 2012 survey [8], 76% of American physicians wrongly thought that better 5-year survival rates are evidence of screening benefits. Furthermore, 47% wrongly considered that more cancers detected in screened than non-screened populations represent evidence that screening saves lives. Only mortality can be used as evidence for screening efficacy. But it is also not that simple.</p><p>The main outcome used to measure screening efficacy is the death rate caused by the screened cancer — cancer specific mortality. There are two problems with cancer-specific mortality. First, it is more common to be overdiagnosed and overtreated than to avoid a death caused by the screened-cancer. For example, in the ERSPC study, which reported a reduction in prostate cancer mortality, 27 men had to be treated to avoid one prostate cancer death [9]. As another example, screening for breast cancer leads to more mastectomies [10]. Moreover, treatment can increase mortality for other causes. For instance, radiotherapy for breast cancer increases mortality for lung cancer and heart disease.10 Thus, to look only for cancer specific mortality could miss deaths caused by treatment. Second, it has been documented that misclassification of the cause death is another source of bias in favor of screening [10]. A good example of how biased cancer specific mortality might be is the Swedish trials of mammography screening: for every 1,000 women screened every other year for 12 years, while one breast cancer death was avoided, the total number of deaths increased by six [11].</p><p>Thus, the only unbiased outcome is overall mortality. Only a reduction in overall mortality actually shows what we want to know: whether screening save lives. The best evidence of a screening reducing overall mortality was for lung cancer using low-dose CT in smokers, but a subsequently systematic review did not find that effect [12]. Since we are dealing with healthy people, a large sample is required to detect a difference in overall mortality. As H. G. Welch wrote in his 2015 book Less Medicine, More Health [13], “we should dump “screening saves lives language.” We should publicly acknowledge that we cannot be sure whether early detection lengthens, shortens, or has no effect on how long people live. And we should be clear that if it takes so many people to find out for sure, then the benefit must be, at best, small.”</p><p>The only way for people who get screened to understand its harms is, as Raffle ended her article, to “avoid contributing myths and fallacies to the debate.”</p><p><strong>References</strong></p><p>1. Raffle, A. 1999. “How long will screening myths survive?” Lancet, 354:431–43</p><p>2. Gigerenzer, G., Gaissmaier, W., Kurz-Milcke, E., et al. 2007. “Helping Doctors and Patients Make Sense of Health Statistics.” Psychological Science in The Public Interest. 8(2):53–96.</p><p>3. Raffle, A.E., Gray, J.A.M. 2007. Screening: Evidence and Practice. Oxford: Oxford University Press.</p><p>4. Wegwarth, O., Gaissmaier, W., Gigerenzer, G. 2010. “Deceiving Numbers.” Medical Decision Making 3: 386–394.</p><p>5. Brodersen, J.,Schwartz, L.M., Heneghan, C., et al. 2018. ‘Overdiagnosis: what it is and what it isn’t.” BMJ Evid Based Med. 23:1–3.</p><p>6. Woloshin, S., Schwartz, L.M., Welch, H.G. 2008. Know Your Chances: Understanding Health Statistics. Berkeley (CA): University of California Press.</p><p>7. Welch, H.G., Schwart, L.M., Woloshin, S. 2000. “Are increasing 5-year survival rates evidence of success against cancer?” JAMA 283: 2975–2978.</p><p>8. Wegwarth, O., L.M. Schwartz, S. Woloshin, et al. 2012. “Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States.” Annals of Internal Medicine 156:340–349.</p><p>9. Fenton, J.J., Weyrich, M.S., Durbin, S., et al. 2018. “Prostate-specific antigen–based screening for prostate cancer: A systematic evidence review for the U.S. Preventive Services Task Force.” Agency for Healthcare Research and Quality, Evidence Synthesis №154. AHRQ Publication №17–05229-EF-1.</p><p>10. Gøtzsche PC, Jørgensen KJ. 2013. “Screening for breast cancer with mammography.” Cochrane Systematic Review.</p><p>Due to overdiagnosis, radiotherapy is used more in screened than non-screened groups. A radiotherapy meta-analysis reported 78% and 27% excess mortality from lung cancer and heart disease, respectively. Bias in cause of death is another issue.</p><p>First, determining the cause of death when patients have multiple diagnoses is a source of error. And, in many mammography screening trials, cause of death was not assessed on blind review, increasing the chance of bias. Furthermore, as radiotherapy reduces the chance of breast cancer local recurrence, it makes it more likely that deaths in screened women with breast cancer will be misclassified as from other causes.</p><p>11. Gøtzsche P.C., Olsen O. 2000. “Is screening for breast cancer with mammography justifiable?” Lancet. 355:129–34.</p><p>12. Prasad, V., Lenzer, J., Newman, D.H. 2016. “Why cancer screening has never been shown to ‘save lives’ — and what we can do about it.” BMJ, 352.</p><p>13. Welch, H.G. 2015. Less Medicine, More Health: 7 Assumptions That Drive Too Much Medical Care. Beacon Press.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=5be177d12d9e" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Screening for Prostate Cancer and Breast Cancer: It’s More Complex Than You May Think]]></title>
            <link>https://felipenogueiraphd.medium.com/screening-for-prostate-cancer-and-breast-cancer-its-more-complex-than-you-may-think-e4f568c7575?source=rss-64c6ffdb6db2------2</link>
            <guid isPermaLink="false">https://medium.com/p/e4f568c7575</guid>
            <category><![CDATA[cancer-screening]]></category>
            <category><![CDATA[breast-cancer-screening]]></category>
            <category><![CDATA[prostate-cancer-screening]]></category>
            <category><![CDATA[screening]]></category>
            <dc:creator><![CDATA[Felipe Nogueira, PhD]]></dc:creator>
            <pubDate>Sat, 01 Jun 2019 19:17:09 GMT</pubDate>
            <atom:updated>2019-06-04T03:04:29.418Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/790/1*yDteEIaLCVcagzq7hRGwCg.png" /></figure><p>Published in <a href="https://www.csicop.org/si/archive/category/volume_43.1"><em>Skeptical Inquirer</em> Volume 43.1 (Jan/Feb 19)</a></p><p><strong>“P</strong>ink October” and “Blue November” are campaigns to promote awareness for breast and prostate cancer respectively. In Brazil, as well in other countries, the population is encouraged to do tests such as the PSA for prostate cancer and mammography for breast cancer</p><p>The main idea is called <em>screening</em>: to perform tests in healthy persons to detect and to treat diseases before their symptoms appear — to increase the cure chances and even to offer a less aggressive treatment. A good example of cancer screening is for cervical cancer, where incidence of the advanced cases decreased after Papanicolaou test was introduced (Adegoke et al. 2012). However, studies that assessed the efficacy of screening for prostate or breast cancer show that in reality things are more complicated than usually advertised by those campaigns.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/731/1*fmwacfIYDdwcPBnfPv6oSQ.png" /><figcaption>Cover of Skeptical Inquirer Jan/Feb 2019</figcaption></figure><p>In May 2018, the U.S. Preventive Services Task Force(USPSTF) reviewed studies of PSA screening for prostate cancer (Fenton et al. 2018). Only two randomized controlled trials were of sufficient quality to assess impact on mortality. One, called the PLCO,* did not show differences in mortality. The second trial, called ERSPC,** showed that screening reduced prostate cancer mortality in men aged fifty-five to sixty-nine. Even in that case, it’s far from simple. In order to avoid one prostate cancer death and three cases of metastatic prostate cancer, 1,000 men aged fifty-five to sixty-nine have to be screened every four years during thirteen years. Of those, twenty-seven men received treatment — prostate surgery and/or radiation therapy. More important, the majority of those who were treated, twenty-four patients, received aggressive treatment with no benefits, only the harms caused by the treatment itself. Regardless of screening, five men died from prostate cancer. See Table 1 for complete estimates.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/504/1*HJCWA7nR7YH5Cs7rN55XMw.png" /></figure><p>The overall picture that prostate cancer screening might cause more harm than good it’s far from new. A 2013 Cochrane meta-analysis (Ilic et al. 2013) of five studies showed no reduction in mortality and in 2012 USPSTF recommended against screening regardless of age. Now, the USPSTF concluded the benefits and harms of screening for men aged 55–69 are balanced, recommending an individualized decision after a careful consideration of potential benefits and harms. For men aged 70 and older, the USPSTF recommended against screening. See <a href="https://www.uspreventiveservicestaskforce.org/Home/GetFileByID/3716">link</a> for USPSTF decision aid.</p><p>Regarding breast cancer, the evidence might look more favorable to screening with mammography, but again not crystal clear as the campaign messages suggest. A 2018 JAMA article (Keating and Pace 2018) estimated that 10 of 10 000 women in their 50s screened annually with mammography during 10 years would avoid breast cancer death. But 940 women would have unnecessary biopsy and 44 would be treated needlessly with surgery, radiation, chemotherapy, or hormonal therapy. Despite screening, 62 women would still die from breast cancer. Since breast cancer treatment improved dramatically as trials were conducted, screening benefits might be even smaller today than those reported in trials (Keating and Pace 2018). To offer benefits while reducing the possible harms, the USPSTF recommends mammography <em>every 2 years</em> for women aged 50–74 and recommends <em>against</em> teaching breast self-examination.</p><p>This situation is not restricted to breast and prostate cancer. Between 1975 and 2009, the incidence of thyroid cancer in United Stated tripled — from 4.9 to 14.4 in 100 000. But the mortality rate remained constant: 0.56 in 100 000 (Esserman et al. 2014). A study in Finland detected thyroid cancers in autopsy of 36% of patients that had died for other causes (Esserman et al. 2014).</p><p>Autopsy studies in prostate in patients that died for other causes also show a great disease reservoir (Sandhu and Adriole 2012). In autopsied men aged 60–79, the incidence of prostate cancer varied between 14 and 77%. Astonishingly, prostate cancer was found even in autopsied men in their twenties, with an incidence of 8–11% (Sandhu and Adriole 2012).</p><p>What these data are describing is called <em>overdiagnosis </em>(Welch and Black 2010; Carter and Barrat 2017). Screening detects mainly non-lethal or harmless cases of cancers — if it weren’t for screening we would die from other causes not even realizing that we also had cancer. Overdiagnosis is not a false-positive result, which is a positive test that subsequent evaluation shows no signs of cancer. In overdiagnosis, the lesion detected actually meets the diagnostic criteria for cancer, but would not have caused symptoms (i.e., it would not have been diagnosed in the absence of screening (Welch and Black 2010; Carter and Barrat 2017).</p><p>Overdiagnosis and its consequences are the main harm of screening. Since at the time of diagnosis, it is impossible differentiate harmless lesions from lethal ones, almost all cases are treated (Welch and Black 2010). Estimates suggest that between 20% and 60% (Fenton et al. 2018; Carter et al. 2015) of screen-detected prostate cancers were overdiagnosed. Of screen-detected breast cancers, overdiagnosis estimate from trials is 19% (Keating and Pace 2018), while an analysis of screening programs reported 52% (Jørgensen and Gøtzsche 2009). Then, a few might benefit from prostate and breast cancer screening, but more patients face harms of aggressive treatment they didn’t even need it in the first place.</p><p>One of the premises of screening is that cancer has a linear progression, which would always allow detection before it’s lethal. But this premise is outdated. Cancers are heterogeneous, with different progression rates (Figure 1) (Carter and Barrat 2017). Screening is more likely to detect cancers that grow slowly or would have regressed. Critically, most lethal cancers, those that grow fast, are less likely to be detected by screening because they tend to cause symptoms between screening rounds (Carter and Barrat 2017).</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/0*qaBJYNW7LYIuV7Hu.png" /><figcaption>Figure 1. Heterogenity of cancer. Not all cancers have the same progression rate (Carter and Barrat 2017; adpated from Welch and Black 2010).</figcaption></figure><p>While the messages encouraging screening tests rarely mention overdiagnosis, they often come with claims like: “If it is early diagnosed, the chances of cure are 95%, but it’s 20% if detected in advanced stage”. However, when overdiagnosis exists, the rate of cured patients is biased — the number of patients that survived cancer increases “automatically” because those patients with new harmless cases are now classified as “cured”, even when screening offers no benefits. Ironically, the rise in cancer incidence and inflated rates of cure due to overdiagnosis might reinforce the efforts to screening leading to even more overdiagnosis (Brodersen et al. 2018).***</p><p>Another way the survival metric is biased relates to how many years the patient has lived after the diagnosis. Screening is only effective if it can detect diseases earlier. Consider for instance that without screening patients are diagnosed due to symptoms at 70 years of age and die at 75. Consider also that these patients would be diagnosed by screening at 65 years and die due to cancer at 75. With these descriptions screening looks beneficial since whoever does screening has a survival of 10 years and who doesn’t only survives 5 years after the diagnosis. In both cases, the patient died at the same time; screening only made the diagnosis to occur earlier, without actually increasing the life expectancy. This is called the <em>lead time bias</em> (Raffle and Grey 2007).</p><p>Due to biases, survival statistics do not show the efficacy of screening. If screening works, incidence of advanced cases must reduce. After the introduction of breast and prostate cancer screening, it was expected an increase in the incidence of early cancers. That should be followed by, as the population ages, a compensatory decrease in advanced cancers, while overall incidence remains unchanged (Esserman et al. 2009). Note in Figure 2 that the incidence of early breast cancers increased significantly, while the incidence of regional cancers decreased very little and rate of distant metastases remained stable. Interestingly, although breast cancer mortality is falling, the fall was larger in young women that were not invited to screening (Narod et al. 2015). In addition, breast cancer mortality decreased in a similar way over the world, but the start of screening differs between countries (Gøtzsche 2015a). Similar observations could be for prostate cancer. After screening, there was not a significant decrease in invasive cases as expected and different rates of screening and treatment in different regions were unrelated to prostate cancer mortality (Esserman et al. 2009). These trend analyses, while does not show causality, indicate that screening leads to considerable overdiagnosis of early disease and its impact on breast and prostate cancer mortality is small at best.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/0*ibCwH5a064Ua-cHR.jpg" /><figcaption>Figure 2. Incidence of different stages of breast cancer standardized by age in the United States White. SEER 9, 1975–2011 (Narod et al. 2015)</figcaption></figure><p>The best approach to measure screening efficacy is using randomized controlled trials, like PLCO and ERSPC. Trials compare screened group with control group, looking for a reduction in deaths caused by the cancer being screened for — what it’s called cancer specific mortality. It is the reduction in cancer specific mortality that prompts the claim that screening “save lives.” But as women <em>overdiagnosed</em> with breast cancer might receive radiotherapy, which increases mortality due to lung cancer (Gøtzsche 2015b), screening could cause more deaths than breast cancer deaths averted. Since deaths by treatment are usually classified as other causes, cancer specific mortality is biased in favor of screening. This bias is avoided by using overall mortality. What might be shocking is that cancer screening trials do <em>not</em> show overall mortality reduction. As Vinay Prasad and colleagues wrote in the<em> BMJ</em> (Prasad et al. 2016), “cancer screening has never been shown to save lives.”**** Does screening increase deaths from other causes? We don’t know — maybe it’s just chance, since millions of people are required in a trial to look for a difference in overall mortality. Prasad and colleagues argued those large trials are needed to know screening effects. In contrast, researcher Peter Gøtzsche think such trials are not an ethical thing to do, since a large number of people would have to be screened without knowing whether this will increase their lives, while it will make them less happy due to psychological distress caused by false-positives results and overdiagnosis (Gøtzsche 2015a). Due to small, if any, benefit in mortality but documented harms, Gøtzsche has stated that mammography screening would have been withdrawal from the market, had it been a drug (Gøtzsche 2015b).</p><p>Other scientists, like Laura Esserman, think that we should focus on ways to make screening better. For example, she and colleagues suggested not to call cancer those indolent cases, which are usually detected by screening (Esserman et al. 2009). Since a cancer diagnosis is associated with a lethal disease that causes suffering in the mind of patients and physicians, renaming those indolent lesions might reduce needlessly treatment. This was firstly proposed almost ten years ago, but as late as August 2018 other scientists are still asking for those changes (Nickel et al. 2018). Esserman has also proposed to move to a risk-based screening, which targets people at high risk of cancer. Testing whether risk-based screening can reduce mammography use without increasing advanced cancers is the objective of the Wisdom study (Esserman et al. 2017).</p><p>Meanwhile, the public needs to be properly informed. The prostate and breast cancer awareness campaigns must be used to clearly tell the population the complexities regarding screening. This is very important; according to surveys women overestimate the benefits of mammography screening by a factor of 10–200 (Wegwarth and Gigerenzer 2018). Also, as screening is often promoted as prevention, 68% of women in a survey wrongly believed that mammography reduces their chance of developing breast cancer (Domenighetti et al. 2003). As a perspective article in <em>New England Journal of Medicine</em> (Biller-Andorno 2014) pointed out, “How can women make an informed decision if they overestimate the benefit of mammography so grossly?” This might be explained by doctor’s failure to communicate screening risk: in a survey of 300 US screening patients, 90% of them had not received information about possible harms of screening by their doctors (Wegwarth and Gigerenzer 2018).</p><p>That’s not the whole story. A 2017 systematic-review showed that doctors usually overestimate screening and treatment benefits while they underestimate its harms (Hoffman and Del Mar 2017). A survey with primary care physicians in the United States suggests that doctors misunderstand screening statistics: 76% of doctors participants were misguided by the survival metric discussed earlier (Wegwarth et al. 2012). They wrongly thought patients diagnosed by screening with better 5-year survival rates than patients diagnosed by symptoms means screening test saved lives. As asked in an article (Wegwarth and Gigerenzer 2018), “Why is risk literacy so scarce in health care?” The authors discussed that the difficulties to access risks and benefits in health likely lies with how statistical information is presented, from biased reports in medical journals to the use of relative risk and misleading statistics by the media. And research shows that decision aids help patients to be more informed regarding screening decisions (Stacey et al. 2014). The researchers beautifully concluded: “A critical mass of informed citizens will not resolve all healthcare problems, but it can constitute a major triggering factor for better care (Wegwarth and Gigerenzer 2018).”</p><p><strong>Notes</strong></p><p>*. PLCO: Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial</p><p>**. ERSPC: European Randomized Study of Screening for Prostate Cancer.</p><p>***. This has been called the popularity paradox: “The greater the harm through overdiagnosis and overtreatment from screening, the more people there are who believe they owe their health, or even their life, to the programme.” (Raffle and Grey 2007, 68).</p><p>**** Lung cancer screening with CT in heavy smokers in a 2011 trial reduced lung cancer and overall mortality. Even though this is case of screening in a high-risk group, Prasad and colleagues considered the best evidence for overall mortality reduction in a cancer screening trial. However, as discussed by the authors, a 2013 meta-analysis for the USPSTF have not shown overall mortality reduction (Prasad et al. 2016).</p><p><strong>Interesting popular readings</strong></p><p>· <em>Overdiagnosed: Making People Sick in the Pursuit of Health</em> by H. Gilbert Welch, Lisa Schwartz and‎ Steve Woloshin (2012);</p><p>· <em>Mammography Screening: Truth, Lies and Controversy</em> by Peter C. Gøtzsche (2012).</p><p><strong>References</strong></p><p>Adegoke, O., S. Kulasingam, and B. Virnig. 2012. Cervical cancer trends in the United States: a 35-year population-based analysis. <em>Journal of Womens Health (Larchmt)</em> 21(10):1031–7. doi: 10.1089/jwh.2011.3385.</p><p>Biller-Andorno, N. 2014. Abolishing Mammography Screening Programs? A View from the Swiss Medical Board. <em>New England Journal of Medicine</em> 370(21): 1965–1967</p><p>Brodersen, J., B.S. Kramer, H. Macdonald, et al. 2018. Focusing on overdiagnosis as a driver of too much medicine. <em>BMJ</em> 362:k3494. doi: 10.1136/bmj.k3494</p><p>Carter, J.L., R.J. Colett, and R.P. Harri. 2015. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods. <em>BMJ </em>350:g7773. doi: 10.1136/bmj.g7773</p><p>Carter, S.M., and A. Barratt. 2017. What is overdiagnosis and why should we take it seriously in cancer screening<em>? Public Health Research and Practice </em>27(3):e2731722. doi: https://doi.org/1017061/phrp2731722</p><p>Domenighetti, G., B. D’Avanzo, M. Egger, et al. 2003. Women’s perception of the benefits of mammography screening: population-based survey in four countries. <em>International Journal of Epidemiology</em> 32:816–21</p><p>Esserman, L.J., H. Anton-Culver, A. Borowsky, et al. 2017. The WISDOM Study: breaking the deadlock in the breast cancer screening debate<em>. npj Breast Cancer</em> 3:34. doi:10.1038/s41523–017–0035–5</p><p>Esserman, L.J., I.M. Thompson, B. Reid, et al. 2014. Addressing overdiagnosis and overtreatment in cancer: a prescription for change. <em>The</em> <em>Lancet Oncology</em> 15: e234-e242. doi: 10.1016/S1470–2045(13)70598–9</p><p>Esserman, L, Y. Shieh, and I. Thompsom. 2009. Rethinking screening for breast cancer and prostate cancer. <em>JAMA</em> 302(15):1685–92. doi: 10.1001/jama.2009.1498.</p><p>Fenton, J.J., M.S. Weyrich, S. Durbin, et al. 2018. Prostate-specific antigen–based screening for prostate cancer: A systematic evidence review for the U.S. Preventive Services Task Force. <em>Agency for Healthcare Research and Quality</em>, Evidence Synthesis №154. AHRQ Publication №17–05229-EF-1.</p><p>Gøtzsche, P.C. 2015a. Commentary: Screening: a seductive paradigm that has generally failed us. <em>International Journal of Epidemiology</em> 244(1): 278–80. doi: 10.1093/ije/dyu267.</p><p>— — — . 2015b. Mammography screening is harmful and should be abandoned. <em>Journal of the Royal Society of Medicine</em> 108(9): 341–345. doi:10.1177/0141076815602452</p><p>Hoffman, T.C., and C. Del Mar. 2017. Clinicians’ expectations of the benefits and harms of Treatments, Screening, and Tests: A Systematic Review<em>. JAMA Internal Medicine</em> 177(3):407–419. doi: 10.1001/jamainternmed.2016.8254.</p><p>Ilic, D., M.M. Neuberger, M. Djulbegovic, and P. Dahm. 2013. Screening for prostate cancer. <em>Cochrane Database of Systematic Reviews</em>, Issue 1. Art. No.: CD004720. doi: 10.1002/14651858.CD004720.pub3</p><p>Jørgensen, K.J., and P.C. Gøtzsche. 2009. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. <em>BMJ</em> 339:b2587. doi: 10.1136/bmj.b2587</p><p>Keating, N.L., and L.E. Pace. 2018. Breast cancer screening in 2018: time for shared decision making. <em>JAMA</em>. doi:10.1001/jama.2018.3388</p><p>Narod, S.A., J. Iqbal, and A.B. Miller. 2015. Why have breast cancer mortality rates declined? <em>Journal of Cancer Policy</em> 5: 8–17 https://doi.org/10.1016/j.jcpo.2015.03.002</p><p>Nickel, B., R. Moynihan, A. Barratt, et al. 2018. Renaming low risk conditions labelled as cancer. <em>BMJ </em>362:k3322 doi: 10.1136/bmj.k3322</p><p>Prasad, V., J. Lenzer, and D.H. Newman. 2016. Why cancer screening has never been shown to “save lives” — and what we can do about it. <em>BMJ</em> 352:h6080 doi: 10.1136/bmj.h6080</p><p>Raffle, A.E., and J.A.M. Gray. 2007. <em>Screening: evidence and practice</em>. Oxford University Press. ISBN 978–0–19–921449–5</p><p>Sandhu, G.S., and G.L Adriole. 2012. Overdiagnosis of prostate cancer. <em>Journal of the National Cancer Institute Monographs</em> (45):146–151</p><p>Stacey, D., F. Légaré, K. Lewis, et al. 2014. Decision aids for people facing health treatment or screening decisions. <em>Cochrane Database of Systematic Reviews</em> CD001431.doi: 10.1002/14651858.CD001431.pub5</p><p>Wegwarth, O., and G. Gigerenzer. 2018. The barrier to informed choice in cancer screening: Statistical Illiteracy in Physicians and Patients. <em>Recent Results in Cancer Research </em>210: 207–221. doi: 10.1007/978–3–319–64310–6_13.</p><p>Wegwarth, O., L.M. Schwartz, S. Woloshin, et al. 2012. Do physicians understand cancer screening statistics? A national survey of primary care physicians in the United States. <em>Annals of Internal Medicine</em> 156:340–9. doi: 10.7326/0003–4819–156–5–201203060–00005.</p><p>Welch, H.G., and W.C. Black. 2010. Overdiagnosis in cancer. <em>Journal of the National Cancer Institute </em>102:605–613</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e4f568c7575" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Did Dogs Become Smart Through Domestication? An Interview with Dr. Brian Hare]]></title>
            <link>https://felipenogueiraphd.medium.com/did-dogs-become-smart-through-domestication-an-interview-with-dr-brian-hare-7fa89fb2a6fb?source=rss-64c6ffdb6db2------2</link>
            <guid isPermaLink="false">https://medium.com/p/7fa89fb2a6fb</guid>
            <category><![CDATA[health]]></category>
            <dc:creator><![CDATA[Felipe Nogueira, PhD]]></dc:creator>
            <pubDate>Sat, 01 Jun 2019 18:36:13 GMT</pubDate>
            <atom:updated>2019-06-01T18:36:13.548Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/600/0*sW6T78l1Rvwh-1kl.jpg" /></figure><p>Published in <em>Skeptic</em> <a href="https://www.skeptic.com/magazine/archives/22.4/">Volume 22 number 4</a></p><p>Translated to Portuguese <a href="http://ceticismoeciencia.blogspot.com/2018/03/cognicao-canina.html">here</a></p><p>Dr. Brian Hare is an associate professor in the Department of Evolutionary Anthropology at Duke University and in the Center for Cognitive Neuroscience. Hare is a pioneer and a key expert in the field of dog psychology. Together with Vanessa Woods, Brian Hare has written about the revolution in the study of dog cognition in the fascinating book <em>The Genius of Dogs: How Dogs Are Smarter Than You Think. </em>The book, in their own words, is “about how cognitive science has come to understand the genius of dogs through experimental games using nothing much more high-tech than toys, cups, balls, and anything else lying around the garage.”</p><p>Hare and other researchers showed many times that dogs are good at understanding humans’ communicative intentions. With the help of a brilliant experiment with foxes begun by Dmitri Belyaev in the 1950s and continuing to the present day, Hare’s research uncovered what allowed dogs to develop this remarkable skill: domestication After 45 generations, Belyaev’s foxes in the experimental group had floppy ears, curled tails, and were much better reading human gestures than the foxes in the control group. The key point is that Belyaev didn’t select for foxes better at reading human gestures; instead he selected for foxes less afraid and friendlier towards humans. As Hare and Woods note in their book: “Domestication, selecting the friendliest foxes for breeding, had caused cognitive evolution.”</p><p>In order to understand even more the limitations and flexibility of canine cognition, researchers have created dedicated laboratories, such the Duke Canine Cognition Center, created by Hare.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/320/0*XHDhcE5fumv7HFaY.jpg" /><figcaption>Dr. Brian Hare</figcaption></figure><p><strong><em>Nogueira: </em>In your book, you talked about the genius of dogs. But what do you mean by being a genius?</strong></p><p><strong><em>Hare:</em></strong> If you’re talking about high IQ, or who is going to be recruited to work for NASA, that would make a very short book. In my opinion, the big discovery in the cognition revolution is that cognition it’s not a unique dimensional trait. Actually, it’s a whole set of skills that can vary independently and we don’t know how many there are. For instance, one can be great at math, but a terrible communicator. Regarding species, <a href="https://www.blogger.com/null">e</a>ach one evolved to solve a set of problems that helped them survive and reproduce in their particular environment; dogs are no different. My book <em>The Genius of Dogs</em> is all about trying to understand how a species that seems utterly unremarkable can can be so successful. Dogs are successful from an evolutionary perspective because, everywhere there are people, there are dogs. It’s the most successful mammal — aside from humans and maybe cows. That’s what the book explores: do dogs have some type of genius psychologically or cognitively? Yes, they show unusual degree of sophistication and flexibility for solving problems.</p><p><strong><em>Nogueira: </em>Tell us how you started researching dog cognition.</strong></p><p><strong><em>Hare: </em></strong>Michael Tomasello, a developmental psychologist and my research supervisor at the time, was explaining to me how important gesture communication is in human development. He thought it was not only crucial to human evolution but something unique to humans. His theory was that kids developed the ability to use human gestures and to understand communicative intention. Then I told him that my dog could do the same thing. That’s when I learned what science is, because even though it was an important idea for how humans evolved, Tomasello became curious. He said to me: “I will help you to come up with a way to prove me wrong.” That’s incredible! When he discovered that he was wrong about dogs, he was excited, telling us to keep doing more experiments. People think science is about people in lab coats coming up with genius ideas, but in reality it’s a way to falsify ideas.</p><p><strong><em>Nogueira: </em>How was the first experiment with dogs?</strong></p><p><strong><em>Hare: </em></strong>We use a powerful, but very simple technique: we hide food in one of two containers. Then we pointed to where we hide it, trying to help the dog search for it. Great-apes are terrible at this task. They don’t show much cognitive flexibility, since they have to learn the gesture. And every time you use a new gesture, they have to learn again. In contrast, in kids around age 12 months, you can use gestures they’ve never seen before, showing a degree of flexibility that it’s not seen in great apes. With dogs we performed the same series of experiments that had been done with apes and human children. The big surprise was that dogs are more like children.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/0*Qebva3PRj8w4Y8mE.PNG" /></figure><p>This was a controlled experiment: dogs were not using their noses nor reacting to motion. In science, there are two steps. First, you have to demonstrate a phenomenon. If it’s gravitational waves or dogs following gesture, you have to demonstrate the phenomenon. Then, you try to explain it. Often, people are so busy trying to explain something before they even demonstrate it exists. Once we demonstrated that dogs were following a pointing gesture, we wanted to know if they, for example, just smelled the hidden food. We found that wolves, dogs and foxes all preferred to use their eyes. When they can’t get the information they need from their eyes, then they use their nose. In these experiments, we found that dogs prioritize information from their eyes and memory over their nose.</p><p><strong><em>Nogueira: </em>One of the fascinating experiments with dogs you mentioned in the book uses an opaque barrier. Could you elaborate on it?</strong></p><p><strong><em>Hare: </em></strong>This is the work of Juliane Kaminsky, Michael Tomasello, and Josep Call. They have placed a ball behind two barriers, one opaque and one transparent. The dog can see both balls. In the experimental condition, a human, on the opposite side of the barriers, asks the dog to fetch the ball. The amazing thing is that dogs didn’t take the ball from the opaque barrier, which the human can’t see through; they favored the ball from the transparent barrier. In the control condition, where the human and the dog are on the same side, seeing the same thing, the dog choose the balls randomly. This experiment suggests that dogs know what humans can or cannot see.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/0*K4mLPu2yZoEcPEIM.PNG" /><figcaption>Experiment conducted by Kaminski et al [2].</figcaption></figure><p><strong><em>Nogueira:</em> What are the possible explanations for why dogs are so good at reading human gestures?</strong></p><p><strong><em>Hare: </em></strong>One level of explanation is that, since dogs have seen these gestures several times, they slowly learned them. You can test this idea by using a gesture they’ve never seen before, for instance, point with your foot. You can also use a crazy gesture, like putting an object on top of the container where the food is located. Human children and dogs follow those gestures, but chimpanzees don’t. So, this hypothesis of slow learning was ruled out. But the hard part is this: how do you know if dogs really have a sophisticated flexible strategy, a theory of mind, which would mean that they’re thinking about the thought of others individuals?. The best evidence about other animals that have a theory of mind comes from great apes and maybe corvids. Regarding dogs, in fact, we don’t have the smoking-gun experiment to rule out alternative explanations. Then, we don’t have overwhelming evidence that dogs really have a theory of mind. For instance, the experiment with the opaque barrier, when the dog knows what people can or cannot see, hasn’t been replicated. Moreover, when you are studying something like a theory of mind, you want multiple experiments where an animal shows the same set of skills. We have that with great apes, but we don’t have with dogs yet.</p><p><strong><em>Nogueira: </em>From where do these remarkable skills of dogs come?</strong></p><p><strong><em>Hare: </em></strong>We tested several hypotheses. The first was that they were related to wolves, which are clever and maybe are also good at reading human gestures. The other was experience: they interacted with us and have slowly learned it. Finally, we considered if it’s something that happened during domestication. The evidence is mostly in favor of domestication: selection for friendliness is what allowed dogs to become more skilled at reading and using humans to solve problems. That was a surprise: why would being selected to be friendly make you smarter?</p><p><strong><em>Nogueira:</em> How has the Belyaev’ fox research helped to answer that question?</strong></p><p><strong><em>Hare: </em></strong>This brilliant experiment was conducted by a group of scientists in Siberia headed by Dmitri Belyaev. They have a control and experimental line of foxes, separated from each other. The control line was bred randomly. In the experimental line, Belyaev selected foxes that were attracted to or enjoyed interacting with people and weren’t fearful. In other words, Belyaev selected friendly foxes and let them breed together. Over many generations, the experimental foxes show a high frequency of traits that Belyaev didn’t select for, such as floppy ears, curly tails, and multi-color coats. The foxes also had physiological changes related to reduction in aggression and increased friendliness. This experiment was important to our research because they have a population that was experimentally domesticated. This was a great opportunity to test the idea that if domestication really is selection against aggression and for friendliness for people. It makes sense: how can you have a domesticated animal if it just wants to attack you or is too scared to come near you? The foxes also led us to questions about psychology: Is this remarkable ability of reading human gestures and to use humans as social tools also a product of selection for friendliness? The answer is yes: the domesticated foxes acted like dogs regarding their ability to read human gestures while the control line did not; they behaved like wolves.</p><p><strong><em>Nogueira:</em> You mention in your book that, “without an experiment, we were slipping from science into the realm of storytelling.” Could you elaborate why we need experiments?</strong></p><p><strong><em>Hare: </em></strong>We published a paper in <em>Science</em> ruling out the first two hypotheses.1 The first is that dogs’ remarkable skills of reading human gestures evolved in wolves and were inherited. Second: lots of experience gives dogs these skills. We didn’t find any evidence for these hypotheses, so by default we favored the domestication hypothesis. We didn’t have evidence for it; we only had evidence against the other two hypotheses. If Belyaev had not done his domestication experiment, we would have been stuck at that point. Belyaev’s work established the possibility of testing if domestication made dogs able to read human gestures. We did an experiment with the foxes and we were surprised: even though they were not selected to be smarter or to be better at using human gestures, they were as a result of being selected for friendliness. We had direct evidence that it was domestication that did it.2People might think that we domesticated dogs and made them smarter, but it does not mean it’s true.</p><p><strong><em>Nogueira: </em>If it’s not true, what probably have happened?</strong></p><p><strong><em>Hare: </em></strong>People tend to think we created dogs as our own image. The best evidence suggests that animals had an advantage if they were friendly to people; they will reproduce more. I was in a restaurant eating outside and there were sparrows stealing food in a few inches of my feet. Those sparrows are eating tons of food, they are fat and healthy. That’s because they’re not afraid of people. I think something like that happened with dogs. In some point of human evolution, humans created a new food resource that if you could be friendly enough and not fearful of human population you were a big-time evolutionary winner. So, a population of wolves chose us; we didn’t choose them. Since hunter-gathers competed with wolves, it does not make sense to bring animal like wolves close to your children. The wolves realized, just like the birds under my table realized, the wonderful resource is scraps around human camps. After a few generations, they would show morphological changes, like those we’ve seen in the foxes, so people could tell the difference between those and the other wolves we competed with. That would be a major selection advantage.</p><p><strong><em>Nogueira:</em> How evolution is related to those changes?</strong></p><p><strong><em>Hare: </em></strong>Selection against aggression and for friendliness toward people creates several changes beyond that in morphology and psychology. Once these new differences are there, selection can act on that too. The point is that these new changes were not created; humans did not think to create dogs with floppy ears, for example. Some individuals had floppy ears because selection against aggression. Then people could breed these individuals to make more floppy ears. In other words, we took the advantage of the variance created by the selection against aggression. Evolution is not any different to gravity. If I drop a ball, I can’t stop it from dropping; it’s unstoppable force. Evolution is also unstoppable. Just because you can’t see, it does not mean it’s not acting all the time. Another example is that there is a white deer that comes to eat in my front yard. Normally, deer coming near humans is a bad idea. If you live in hundred yards from my house, a deer in your front yard would soon be dinner. But where I live in the suburbs everybody think deer are cute and adorable. Where I live, there is higher proportion of deer with different color coats; there are more white and albino deer. Research already shows that deer that are invading urban areas are larger, more social and have more offspring than deer living far away from humans.*</p><p><strong><em>Nogueira:</em> This process of domestication that happened with dogs probably have happened with other animals well, which we called convergence of evolution. What do we find, for example, when we compare chimpanzees and bonobos behavior regarding aggression, attitudes towards strangers and so on?</strong></p><p><strong><em>Hare:</em></strong> Bonobos served as a test-case for the hypothesis that natural selection, and not artificial selection, caused domestication. We called it self-domestication: species, through natural selection interfacing with its environment, end up like a domesticated animal. When we compare chimpanzees and bonobos to wolves and dogs, many changes between wolves and dogs were found between chimpanzees and bonobos. Chimpanzees are like the wolf of the ape family. Weather we’re talking about morphological or behavior characteristics, bonobos are really the dog of the Ape family.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/0*EwljuwVmP0ffmHvF.PNG" /></figure><p><strong><em>Nogueira: </em>At Skeptic, we advocate for evidence-base thinking. Since you had communicated with the public, what do you think is the best approach to shift people from faith-based thinking to evidence-based thinking, increasing, for example, the acceptance of evolution?</strong></p><p><strong><em>Hare</em></strong>: In US, people think that Christians have a problem with evolution, but the Catholic Church says evolution is consistent with Catholic doctrine. People love to play the “in and out” group card: science is something that other people do. If one is religious and faithful, one can’t believe in science, since science is anti-religion. That’s the typical in-out group response. People use strategies to target science, or evolutionary thinking, as the out group. As someone who studies evolution, the first thing is to notice that humans evolved to see in-out group everywhere. If you say something like “you’re religious and you’re not like me”, it’s over. As a science communicator, I’m going to say that Catholic Church has no problem with my research in order to turn-off the in-group out-group response. The entire intent of my book <em>The Genius of Dogs</em> is to get people who had never read about evolution and cognitive science excited to read about it, because they care about dogs. Darwin intentionally started <em>The Origins of Species</em> with a chapter about domestication, because he knew people were familiar with and were not threaten by it. I think we have to do the same thing.</p><p><strong><em>Nogueira:</em></strong> Thank you for this amazing interview and keep up the fascinating research!</p><p><strong>References</strong></p><p>1. Hare B, Tomasello M. 2005. Human-like social skills in dogs? Trends in Cognitive Sciences 9: 439–444. <a href="https://www.ncbi.nlm.nih.gov/pubmed/16061417.">https://www.ncbi.nlm.nih.gov/pubmed/16061417.</a></p><p>2. Kaminski J, Bräuer J, Call J, Tomasello M. 2009. Domestic dogs are sensitive to a human’s perspective. Behaviour 146: 979–998 <a href="https://doglab.shh.mpg.de/">https://doglab.shh.mpg.de/</a> pdf/Kaminski_et_al_2009a_dogs_sensitive_humans _perspective.pdf.</p><p>3. Hare, B Hare, B., Homo sapiens Evolved via Selection for Prosociality. Annu Rev Psychol. 68:155–186: <a href="https://www.ncbi.nlm.nih.gov/pubmed/27732802">https://www.ncbi.nlm.nih.gov/pubmed/27732802</a></p><p>4. Hare B., M. Brown, C. Williamson, and M. Tomasello. 2002. “The domestication of social cognition in dogs.” <em>Science</em>. 298: 1634–6.</p><p>5. Hare B., et al. 2005. “Social cognitive evolution in captive foxes is a correlated by-product of experimental domestication.” <em>Current Biology</em>. 15: 226–30.</p><p><strong>Notes</strong><br>* Here I corrected a minor mistake that was published in the original version. I also corrected Figure 2’s subtitle: the correct reference number is 2 (Kaminski <em>et al</em>, 2009).</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7fa89fb2a6fb" width="1" height="1" alt="">]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Where Drugs Myths Die. An Interview with Dr. Carl Hart]]></title>
            <link>https://felipenogueiraphd.medium.com/where-drugs-myths-die-an-interview-with-dr-carl-hart-26cc04834c83?source=rss-64c6ffdb6db2------2</link>
            <guid isPermaLink="false">https://medium.com/p/26cc04834c83</guid>
            <category><![CDATA[science-policy]]></category>
            <category><![CDATA[drugs]]></category>
            <category><![CDATA[science]]></category>
            <category><![CDATA[interview]]></category>
            <category><![CDATA[drug-policy]]></category>
            <dc:creator><![CDATA[Felipe Nogueira, PhD]]></dc:creator>
            <pubDate>Thu, 30 Aug 2018 06:12:00 GMT</pubDate>
            <atom:updated>2018-09-04T21:58:24.470Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/600/0*kpgt0S8wYXSdDExz.jpg" /><figcaption>Interview with Carl Hart — <em>cover story on </em>Skeptic</figcaption></figure><p>Published in <em>Skeptic</em> <a href="http://www.skeptic.com/magazine/">Volume 20 number 2</a></p><p>(article translated to portuguese on <a href="http://ceticismoeciencia.blogspot.com.br/2015/08/destruindo-mitos-sobre-as-drogas.html">link</a>)</p><p>By Felipe Nogueira</p><p>Carl Hart is an associate professor in the departments of Psychology and Psychiatry at Columbia University, and a research scientist in the Division of Substance Abuse at the New York State Psychiatric Institute. He is a member of the National Advisory Council on Drug Abuse and on the board of directors of the College on Problems of Drug Dependence and the Drug Policy Alliance. After receiving his B.S. in psychology at the University of Maryland and his Ph.D. in experimental psychology and neuroscience at the University of Wyoming, he went on to publish many papers in prestigious scientific journals for which he was made a Fellow by the American Psychological Association. In 2012 he co-authored with Charles Ksir the highly regarded textbook <em>Drugs, Society, and Human Behavior </em>(McGraw-Hill).</p><p>As a neuropsychopharmacologist Dr. Hart researches the effects of drugs on human physiology and behavior. For example, one of his experimental objectives was to understand how crack cocaine users would respond when given a choice between the drug and another appealing option — money. Contrary to what most people would think, Hart’s experiment revealed that drugs users can behave rationally, choosing other appealing options than destructive drugs. Thus, the medical model of addiction that treats it like a disease is not fully accurate when compared with, say, AIDS or cancer, which patients cannot simply choose not to have. Many people do quit drug use, even addicts. The question is, why?</p><p>Being a distinguished drug scientist is only part of Hart’s fascinating personal history with drugs. He was raised in a poor neighborhood in Miami where in high school he not only used drugs but also sold marijuana, and in the process committed petty crimes. To make matters worse, most of his relatives didn’t recognize the value of a formal education, so he ended up joining the United States Air Force, which gave him a deeper appreciation of the importance of knowledge, especially scientific knowledge and the ability to think critically, eventually leading him to become the first African-American tenured science professor at Columbia University.</p><p>In 2013, he published <em>High Price: A Neuroscientist’s Journey of Self-Discovery that Challenges Everything You Know About Drugs and Society</em> (Harper), a book about research, myths, laws and public policy about drugs written for a general audience. The book is also a memoir, where Hart discusses his personal life and how he turned out to be the scientist he is now. <em>High Price</em> received the 2014 PEN E.O. Wilson Literary Science Writing Award, and he has since appeared as a regular guest on talk shows such as Bill Maher’s Real Time on HBO, where on the September 27, 2013 show the host made his usual plea for the legalization of marijuana, to which Dr. Hart added that cocaine, heroine, and methamphetamines should also be decriminalized so that people can get the help they need and we can empty out our prisons of such victimless crimes. He schooled Bill O’Reilly on the facts about addiction (texting doesn’t count), pointed out to him that the last three presidents of the United States smoked pot in their youth, and that, in fact, marijuana use among high school kids has declined from 37% in 1978 to 22% today (O’Reilly insisted it was higher, to which Dr. Hart responded bluntly “you’re wrong”).</p><p>In this sense Carl Hart is the mythbuster of drugs, the debunker of addiction myths, and a true skeptic of the pseudoscience and nonsense underlying this country’s attitudes about drugs and drug addicts.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/0*_pPErf-5EOl0jUJK.jpg" /></figure><p><strong><em>Skeptic: </em>Many people believe marijuana is a gateway drug. Is it?</strong></p><p><strong><em>Hart</em></strong><em>:</em> It all depends what is meant by “gateway drug”. What people often mean is that marijuana leads to hard drugs. That is not true. It <em>is</em> true that the vast majority of people who use heroin and cocaine, for example, used marijuana before they used these hard drugs. But, then you look at the fact that the vast majority of marijuana smokers don’t go on to use those drugs. So, it’s not a gateway drug. It’s illogical to make that sort of statement. It would be like saying that “the last three presidents of United States used marijuana before they became president. Therefore, marijuana is a gateway drug to the white-house.”</p><p><strong><em>Skeptic: </em>Those who use crack cocaine didn’t use alcohol or tobacco before using marijuana?</strong></p><p><strong><em>Hart</em></strong><em>:</em> Most used alcohol and tobacco before they used crack cocaine; of course, they also drank water or ate a fruit. Crack cocaine users engaged more in petty crimes than those who use marijuana, so we can also say petty crimes is a gateway to harder drugs. You can think of any number of behaviors associated with people who go on to use heroin and call those behaviors gateway, but that’s not a proper scientific conclusion to draw.</p><p><strong><em>Skeptic: </em>Is there a difference between crack and cocaine?</strong></p><p><strong><em>Hart</em></strong><em>:</em> Pharmacologically, there is no difference. The major thing the people are seeking when they use cocaine is the cocaine base. Powder cocaine contains not only the base, but a hydrochloride salt that makes it stable and decreases the likelihood to smoke it. If you want to smoke it, you have to remove the hydrochloride portion, which does not contribute to biological effects of cocaine. When people are describing the difference between crack cocaine and powder cocaine, what they are really describing is the difference between the ways the drugs are taken. The onset of effects is faster when you smoke it than when you snort it. But you can dissolve powder cocaine in water and inject it in your veins and have the same effect as you do from smoking the crack.</p><p><strong><em>Skeptic: </em>Since it hits the brain faster, is crack more addictive than cocaine?</strong></p><p><strong><em>Hart</em></strong><em>:</em> Smoking crack cocaine and injecting powder cocaine dissolved in water hits the brain at the same speed. Nonetheless, this is one of the arguments that some have made. But there is no drug that we punish as a result of the route of administration besides crack cocaine and powder cocaine. And we make that distinction in the United States because crack cocaine was associated with poor black people. When we look to powder cocaine in United States in the early 1980s, there was no drug that produced more violence than powder cocaine, but no one passed new laws, in part, because the people engaged were not black people; they were primarily white people. So as a society we are not being honest about this.</p><p><strong><em>Skeptic: </em>People think one dose is enough to get them addicted. Can you explain why this is not true?</strong></p><p><strong><em>Hart</em></strong><em>:</em> By definition, drug addiction is behavior that disrupts your psychosocial functions, your job, your family life, and the behavioral disruptions have to occur on multiple occasions. So, if you use a drug once and you have a disruption once, by definition that is not an addiction. Addiction requires work. There is no <em>one</em> hit of anything that causes anyone to get addicted. People make these statements based on pure hyperbole attempting to get an emotional rise out of the listener.</p><p><strong><em>Skeptic</em>: How addictive is tobacco compared to other drugs?</strong></p><p><strong><em>Hart</em></strong><em>:</em> At 1 in 3, or 33% of people who smoke will become addicted to tobacco, that is the drug that we say causes the most addiction. By comparison, 15% of those who use alcohol will become addicted. The rate for marijuana is about 10%. Heroin is about 25%, and cocaine (and crack cocaine) ranges from 15% to 20%.</p><p><strong><em>Skeptic: </em>Psychopharmacologist David Nutt, author of <em>Drugs Without the Hot Air</em>, published a study in 2010 that called alcohol the most harmful drug. Do you agree with this?</strong></p><p><strong><em>Hart</em></strong><em>:</em> I am a fan of David’s work and of his advocacy to educate the public, and I admire what he does. I think he tries to make the public understand that when we think about whether a drug is toxic, we have to look to multiple measures. And in one measure alcohol may be seen as the most toxic drug. For example, when we think about withdrawal from a drug, when people abruptly discontinue long-term use of a drug alcohol is clearly the most dangerous because you can actually die from alcohol withdrawal. You can’t die from withdrawal from heroine, crack cocaine, tobacco, or marijuana. When trying to determine the potential toxicity of a drug, it all depends on what measure you’re looking at.</p><p><strong><em>Skeptic: </em>I’ve heard a lot of comments about how addictive people behave. For example, some people say crack users are “zombies”. I’m not sure what it means to be a drug zombie, but what is it people are thinking when they use such expressions to describe people under the influence of a drug? That is, how do addicted people behave?</strong></p><p><strong><em>Hart</em></strong><em>:</em> I’m a psychologist who studies human behavior. But all of us behave, and we most of us think we’re experts in understanding human behavior because of this fact. But most people are not experts and that’s part of the problem with such subjective and anecdotal reports. People see somebody misbehaving in some way and they know that person uses a drug. Therefore, they conclude that the misbehavior is caused by that substance. No! You can’t draw that conclusion. There are multiple factors at work, and these multiple factors need to be teased apart. You have to consider the person’s psychological history, whether or not other drugs were on board, whether the person was sleep deprived, whether the person interacted with someone who angered them, etc. People often fail to consider these other factors. That’s why anecdotes alone are insufficient to provide an adequate explanation of behavior.</p><p><strong><em>Skeptic: </em>In one of your experiments you gave participants two choices, money or drugs. What did you find and what does it mean?</strong></p><p><strong><em>Hart</em></strong><em>:</em> Of the things people say about drugs users, particular about the drug addicted, is that they only respond to their drug of choice: if you give them an opportunity to use their drug, they’re going to take it over anything else. It was a simple experiment in which we had escalating amounts of money that we offered subjects. We found that when you increase the monetary value, you decrease their choice to take the drug — they choose money instead; they behaved rationally.</p><p><strong><em>Skeptic: </em>Why do people get addicted?</strong></p><p><strong><em>Hart</em></strong><em>:</em> It’s a difficult question and one that science should be really focused on. Recently we’ve been concentrating on finding biological mechanisms of addiction. But frankly we’ve not found any that are compelling so we must look to other things as well, such as co-occurring psychiatric illnesses like depression, anxiety, and schizophrenia, which increase the likelihood of being addicted. Addiction is a condition primarily characterized by not tempering your behavior when it comes to certain drugs. But there are people who do not temper their behavior in a wide variety of domains, not just with drugs, because they just haven’t learned the skills to do that. So, that increases the likelihood of becoming addicted if they indulge in drug-taking behavior because taking a drug requires a person to be responsible, for example when driving an automobile. You can’t be irresponsible driving automobile; you might hurt yourself or someone else. If you haven’t learned those responsibility skills, it increases the likelihood of you becoming addicted. If you don’t have many alternatives in life that are better than drugs, it increases the likelihood of you becoming addicted. All these factors are critically important when we’re trying to determine why someone became addicted compared to someone else who did not.</p><p><strong><em>Skeptic: </em>You mentioned biological mechanisms for addiction. There is the dopamine hypothesis, but you mentioned in your book that there are problems with it. Can you clarify?</strong></p><p><strong><em>Hart</em></strong><em>:</em> Let’s talk about the simplistic version of the dopamine hypothesis first. Drugs like cocaine and amphetamines increase dopamine, which in turn increases pleasure. So researchers said drug users are trying to increase their dopamine and so dopamine was considered to be a critical factor. This was an important theory because it helped us to organize several types of experiments, but it came about in 1960s when we had identified only five or six neurotransmitters. Today, we know about more than 100 neurotransmitter substances and yet the theory hasn’t been appreciably updated. So, we’ve learned a lot about the complexity of the brain in terms of how neurotransmitters interact with each other. Rather than one neurotransmitter being released at one time, there are multiple neurotransmitters that are released together in order to produce effects. And, sometimes, they are co-localized in the same cells. The old dopamine theory does not take into account this new knowledge. For me, the dopamine hypothesis is too simple to explain complicated behavior. Plus, we have some observable information that can help people right now: Does the person have a co-occurring disorder? Is the person responsible? We can manipulate many variables to help people now; you can’t assist drug users immediately with the dopamine hypothesis, and it doesn’t help anybody in treatment; it doesn’t help in any practical level. It’s on the level that science is trying to figure it out and we’re not close, if we’re talking about dopamine.</p><p><strong><em>Skeptic: </em>What about pharmacological treatments for drug addiction, such as cocaine?</strong></p><p><strong><em>Hart</em></strong><em>:</em> A large part of my career has been spent trying to develop medications to help people with cocaine addiction, but we have been unsuccessful in finding a medication that works. It seems the best medication for cocaine addiction is cocaine itself. In Switzerland heroin is used to treat heroin addiction, and successfully so. When we think about treatment there are a variety of components that are necessary, not only the drug: psychosocial support, therapy to figure it out what’s going on with the person’s addiction, do they have employment, do they have a social network? All of these factors are incorporated into the heroin treatment program in Switzerland, and it’s been successful. You can do a similar thing with cocaine, but you have to have all these other auxiliary components in place.</p><p><strong><em>Skeptic:</em> What are the harms caused by amphetamines?</strong></p><p><strong><em>Hart</em></strong><em>:</em> The first lesson people should really know is that there are potential harms for all the drugs that we’ve talked about it. However, when you only emphasize the potential harms, people who use drugs stop listening to you, because they know there are other effects (that’s why they use them). The major concern about amphetamines is that they have a powerful effect on the cardiovascular system; it increases blood pressure and heart rate. This is not good for people who have a compromised cardiovascular system; they should not take large doses of amphetamines. Amphetamines disrupt sleep, and sleep deprivation can cause several physical and psychological problems, even without any drugs use. Amphetamines also disrupt food intake, which is critically important for the proper functioning of the body. Those are the concerns that people who take amphetamines should be aware of, rather than other concerns that are often emphasized in the media and even by scientists. About cognitive decline, amphetamines are approved to enhance cognitive functioning in order to treat attention deficit disorder. So, the notion that amphetamines are causing cognitive dysfunction is simply inconsistent with the history of behavioral science we have with these drugs.</p><p><strong><em>Skeptic:</em> Another idea you hear a lot is that marijuana or cocaine kills nerve cells. Is that any evidence of that?</strong></p><p><strong><em>Hart</em></strong><em>: </em>Any psychoactive drugs in large doses can kill brain cells. However, these doses are so large that they the drugs would be so unpleasant to humans that they wouldn’t take those doses again after experiencing their effects, if they survived it. These doses are 20–80 times of what people usually takes. In addition, there is no evidence that long-term use of doses within the range that humans take produces neurotoxicity. Neurotoxicity certainly can happen, but the likelihood that it happens to people using drugs within the range that humans take is very low.</p><p><strong><em>Skeptic:</em> Why do you advocate for decriminalization rather than legalization of drugs?</strong></p><p><strong><em>Hart</em></strong><em>:</em> Of all these drugs that we’ve talked about, nicotine in tobacco is probably the one that kills you with the smallest amount of it. 50 mg of nicotine would kill half of us. In contrast, with 50 mg of cocaine or heroin, you just feel really nice. So, we have to think why nicotine is legal even though so little of it is necessary to kill people. It’s legal because we have societal structures, we have education about nicotine, and we know how to keep people safe with it. One cigarette contains 1 mg of nicotine and one pack contains 20 cigarettes. It requires people to smoke multiple packs immediately to kill themselves. We’ve packaged nicotine in a way that substantially decreases the likelihood of someone getting immediately harmed. We have to figure out how to package other drugs and educate people in a way to keep them safe. We have not done that yet, because we don’t have the social structures in place. I see decriminalization, in part, as the intermediary step to regulation, like we regulate alcohol and tobacco. But we have to put those structures in place to keep people safe, because all of these drugs are potentially dangerous, although all of them can be used safely.</p><p><strong><em>Skeptic:</em> We can compare different places (countries, states, cities) with different drugs laws (prohibited, decriminalized, legalized) regarding several outcomes, such as rates of drug use, drug-related deaths, drug-related homicides, and crime. What can we say about these kinds of measurements? That is, what are the effects of decriminalization and legalization on such outcomes?</strong></p><p><strong><em>Hart</em></strong><em>: </em>I think a comparison of Portugal and the U.S. would be instructive here. In 2001, Portugal decriminalized all drugs including heroin and cocaine. Overall, they have increased spending on prevention and treatment, and decreased spending for criminal prosecution and imprisonment. The number of drug-induced deaths has dropped, as have overall rates of drug use, especially among young people (15–24 years old). In general, drug use rates in Portugal are similar, or slightly better, than other European Union countries, and they are doing better than us in the U.S. In other words, Portugal’s decriminalization has been successful. No, it didn’t stop all illegal drug use. That would have been an unrealistic expectation. Portuguese continue to get high, just like their contemporaries and all human societies before them. But they don’t seem to have the problem of stigmatizing, marginalizing, and incarcerating substantial proportions of their citizens for minor drug violations. Together, these are some of the reasons that I think decriminalization, or even legalization should be considered as potential options in the United States.</p><p><strong><em>Skeptic: </em>If you were the director of drug control polices in United States, what would be your short- and long-term policies?</strong></p><p><strong><em>Hart</em></strong><em>: </em>I would first work to decriminalize all drugs so that people no longer run the risk of being incarcerated for drug possessions. Too many of our citizens are languishing in prison unnecessarily for drug violations. I would also work to change the way we educate about drugs such that it would no longer be acceptable to exaggerate the harms of drugs as a scare tactic. Education would first function to keep our citizens safe. In the long-term, I’d work to regulate all drugs so that we decrease the likelihood of drug users obtaining and using drugs that are adulterated with chemicals more dangerous than the drugs themselves. My major goal as director would be keeping people safe, with the understanding that some people will use drugs as humans have always done.</p><p><strong><em>Skeptic: </em>What was your goal when you wrote the book <em>High Price</em>?</strong></p><p><strong><em>Hart</em></strong><em>: </em>The goal was to communicate to the general public. The first goal of the scientific community is to keep their lab funded and, sometimes, this is inconsistent with larger goals of society. The research on drug abuse is mainly focused on the bad effects of drugs, because the major funder is National Institute of Drug Abuse, which funds 90% of world’s research in this area. National Institute of Drug Abuse goal is focused on the bad things that happen with drugs, and scientists are shaped by this goal. Society at large has the goal of being safe, and scientists have the goal of “don’t use these drugs”, so it’s inconsistent. I wanted to make the public understand that their goal and the scientist’s goal are different, that their goal and the goal of the police man who is talking to them are different, and that their goal is also different from the goal of media person who writes stories about drugs.</p><p><strong><em>Skeptic: </em>At <em>Skeptic</em> we advocate for evidence-based instead of faith-based thinking, as do you. What do you think is the best approach to shift people from faith-based to evidence-based thinking?</strong></p><p><strong><em>Hart</em></strong><em>:</em> When you try to change people’s view about something that they think they know, in some cases they feel threatened and insulted because they worked really hard to acquire this knowledge. Now you tell them they’re wrong, and that’s hard for most of us to accept. So, the approach has to be one that acknowledges the work they have put in to acquire their knowledge, even if their knowledge is outdated or inaccurate. On the one hand, you say “you know, I was just like you, I got fooled. They fooled me, like they just fooled you. Here it’s how I see it differently now, and how you can see it differently too.” You have to make some connection with the audience, with the people, in order to move them along. Sometimes we all get impatient because we don’t have the time to make the connection, so we say “the evidence shows this and you’re wrong.” That usually doesn’t work. I understand why people become impatient because they hope others will just follow the evidence like they do, but it doesn’t work that way on a regular enough basis.</p><p><strong><em>Skeptic</em></strong><em>: </em>What do you think is critical to being a good scientist?</p><p><strong><em>Hart</em></strong><em>:</em> Always to try to disprove your own hypothesis. If you’re not doing that, you increase the likelihood of following dogma. So the critical thing is to design experiments that can disprove your own hypothesis.</p><p><strong><em>Skeptic</em></strong>: Thank you for this thoughtful interview.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/400/0*J41ZdFwky2zioSA6.jpg" /></figure><p><em>Originally published at </em><a href="http://skepticismandscience.blogspot.com/2015/11/where-drugs-myths-die.html"><em>skepticismandscience.blogspot.com</em></a><em> on August 9, 2015.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=26cc04834c83" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>